Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States

Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is effective for reducing human immunodeficiency virus (HIV) acquisition among cisgender women. We report results from the first US observational open-label demonstration project of pre-exposure prophylaxis (PrEP) among at-risk cisgend...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical infectious diseases 2021-10, Vol.73 (7), p.1149-1156
Hauptverfasser:	Blumenthal, Jill, Jain, Sonia, He, Feng, Amico, K Rivet, Kofron, Ryan, Ellorin, Eric, Stockman, Jamila K, Psaros, Christina, Ntim, Gifty M, Chow, Karen, Anderson, Peter L, Haubrich, Richard, Corado, Katya, Moore, David J, Morris, Sheldon, Landovitz, Raphael J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Anti-HIV Agents - therapeutic use Emtricitabine Female HIV Infections - drug therapy HIV Infections - prevention & control Humans Major and Commentaries Medication Adherence Middle Aged Pre-Exposure Prophylaxis Tenofovir United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!